Roby Thomas, MD, discusses the shortage of lutetium Lu 177 vipivotide tetraxetan, and how it had affected patients with metastatic castration-resistant prostate cancer being treated at UPMC Hillman Cancer Center.
Roby Thomas, MD
Advertisement
Roby A. Thomas, MD, is a medical oncologist and hematologist at UPMC Hillman Cancer Center. Thomas focuses genitourinary and gastrointestinal malignancies.
Articles by Roby Thomas, MD
Roby Thomas, MD discusses chemotherapy shortages and the impact these shortages have had on oncology research.
Roby Thomas, MD, the ongoing shortage of the PSMA-targeted radionuclide therapy, Pluvicto and the impact it is having on prostate cancer care.
Roby Thomas, MD, provides ideas for oncologists to consider while multiple chemotherapy drug are on shortage in the United States.
Advertisement
Latest Updated Articles
Prior Pluvicto Shortage Led to Long Waiting Lists for Patients With mCRPCPublished: July 22nd 2023 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
